Table 1.

Results of a multivariate regression analysis of tolvaptan treatment effect on change in eGFR to month 36 in TEMPO 3:4

Parameter	Estimate	95% CI	P Value
Intercept, %	−10.35	−16.32 to −4.39	0.00068
Age, yr	−0.209	−0.343 to −0.074	0.00237
Sex (1, male; 2, female)	2.671	0.791 to 4.551	0.00539
Model with treatment and the above predictors (0, placebo; 1, tolvaptan)
Treatment, %	3.72	1.78 to 5.66	0.00018

CI, confidence interval.